Featured Research

from universities, journals, and other organizations

New system for therapy of metastatic spinal tumors

Date:
July 11, 2011
Source:
Universität Mainz
Summary:
A new system for the treatment of spinal tumors is a combination of radiofrequency ablation, which uses the heat energy of radio frequency waves to ablate and destroy tumors, and subsequent kyphoplasty, by which the spine is stabilized through the injection of bone cement as filler material. A recently started single-center study involving 10 evaluable patients suffering from painful metastatic spinal tumors is now expected to provide information about the efficacy of this method.

The Orthopedic Clinic and Policlinic at the University Medical Center of Johannes Gutenberg University Mainz (JGU) has recently deployed a new system for the treatment of spinal tumors for the first time. This treatment is a combination of radiofrequency ablation, which uses the heat energy of radio frequency waves to ablate and destroy tumors, and subsequent kyphoplasty, by which the spine is stabilized through the injection of bone cement as filler material. A recently started single-center study involving 10 evaluable patients suffering from painful metastatic spinal tumors is now expected to provide information about the efficacy of this method.

"The results of this trial will provide critical information about the safety and efficacy of minimally invasive targeted radiofrequency ablation to treat vertebral metastates," says Professor Dr med Andreas Kurth, Director of the Orthopedic Clinic at the University Medical Center of Johannes Gutenberg University Mainz. "We are confident that this advanced method employed for tumor reduction and simultaneous stabilization of the spine through bone-sparing kyphoplasty will minimize the cancer patient's severe discomfort while stabilizing the vertebra."

The Spinal Tumor Ablation with Radiofrequency (STAR)™ System of DFINE, Inc., which was jointly developed with the Orthopedic Clinic of Mainz University Medical Center, is already FDA-approved as a device permitting minimally invasive targeted tumor necrosis of metastatic spinal tumors. Following ablation with the STAR System, vertebra(e) will be stabilized with ultra-high viscosity cement. This minimally invasive procedure generally takes about an hour. The data to be perceived from the Evaluation of Combined RF Ablation and Cement Delivery in Painful Tumors of the Spine Trial (AbCT) are to support the filing for Conformité Européenne (CE) Mark certification in 2012.

In the United States alone, 13 percent (190,000 cases) of the 1.5 million new cancer cases diagnosed annually will develop spinal mestasis. Beyond narcotic administration and traditional pain management, the primary modality for treating spinal metastases is external beam radiation. While this represents the current standard of care for treating metastatic cancer, pain relief often requires multiple treatments and weeks to be effective. In addition, radiation therapy often requires that patients suspend chemotherapy treatment of the primary cancer due to cumulative toxicity. Using the DFINE minimally invasive procedure to treat painful metastatic spinal lesions provides immediate pain relief and an improved quality of life. There is also minimal, if any, delay in systemic, curative therapy of the primary cancer therapy -- a significant benefit for the patient.

The STAR™ System of DFINE incorporates a unique bipolar navigational instrument, which offers unparalleled control and enables the physician to overcome many of the technical challenges which have limited targeted ablation in boney tissues to date. "Due to the critical anatomy in the spine and the invasive nature of conventional surgical procedures to treat spinal metastases, we believe DFINE's minimally invasive therapy that allows targeted delivery of radiofrequency energy for ablation of tumors may provide the fastest and most effective relief from the painful effects of spinal metastases, and thereby represents a significant advance in the patient's treatment," states Kurth.


Story Source:

The above story is based on materials provided by Universität Mainz. Note: Materials may be edited for content and length.


Cite This Page:

Universität Mainz. "New system for therapy of metastatic spinal tumors." ScienceDaily. ScienceDaily, 11 July 2011. <www.sciencedaily.com/releases/2011/07/110711081254.htm>.
Universität Mainz. (2011, July 11). New system for therapy of metastatic spinal tumors. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/07/110711081254.htm
Universität Mainz. "New system for therapy of metastatic spinal tumors." ScienceDaily. www.sciencedaily.com/releases/2011/07/110711081254.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins